Storia in 6 fonti

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks

Heart disease is is the leading cause of death for people with Type 2 diabetes

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

independent.co.ukStai leggendo1 g fa

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks

Heart disease is is the leading cause of death for people with Type 2 diabetes

originale

Timeline cronologica

time.com

1 g fa

Mounjaro Is Now Approved to Lower the Risk of Heart Events

The new indication for Eli Lilly's drug is for people with Type 2 diabetes.

Leggi questa versione → originale

qz.com1 g fa

FDA approves Mounjaro to lower heart attack and stroke risk

The diabetes drug, already the top-prescribed branded type 2 diabetes medicine in the U.S., showed an 8% lower rate of major heart events than Lilly's older drug Trulicity

Leggi questa versione → originale

morningstar.com1 g fa

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

Leggi questa versione → originale

healio.com2 g fa

Mounjaro approved to reduce cardiovascular events in adults with diabetes

The FDA has approved tirzepatide for reduction of cardiovascular risk in adults with type 2 diabetes, Eli Lilly announced.Tirzepatide (Mounjaro), a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor…

Leggi questa versione → originale

fiercepharma.com1 g fa

Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo Nordisk. | In their high-profile competition in the diabetes and obesity markets, Eli Lilly…

Leggi questa versione → originale

venerdì 28 agosto 2026·

fiercepharma.com

Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo Nordisk. | In their high-profile competition in the…

venerdì 28 agosto 2026·

qz.com

FDA approves Mounjaro to lower heart attack and stroke risk

The diabetes drug, already the top-prescribed branded type 2 diabetes medicine in the U.S., showed an 8% lower rate of major heart events than Lilly's older drug Trulicity

venerdì 28 agosto 2026·

independent.co.uk

Weight-loss drugs could help treat other health conditions. Here’s what could be next

The U.S. FDA on Friday approved the use of Eli Lilly's Mounjaro to reduce the chances of heart attack or stroke in high-risk patients with type 2 diabetes

venerdì 28 agosto 2026·

time.com

Mounjaro Is Now Approved to Lower the Risk of Heart Events

The new indication for Eli Lilly's drug is for people with Type 2 diabetes.

venerdì 28 agosto 2026·

independent.co.uk

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks

Heart disease is is the leading cause of death for people with Type 2 diabetes